AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Pulmatrix, a biopharmaceutical company, has mutually agreed with Cullgen to waive the "No Solicitation" clause in their merger agreement, allowing both parties to explore alternative transactions while continuing to seek approval from the China Securities Regulatory Commission. The waiver will enable Pulmatrix and Cullgen to explore other options while still pursuing the merger.
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet